GERN:NGS-Geron Corporation (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 3.7

Change

-0.03 (-0.80)%

Market Cap

USD 0.34B

Volume

4.67M

Analyst Target

USD 4.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Geron Corp is a biopharmaceutical company that supports the clinical stage development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies, by Janssen Biotech, Inc., or Janssen.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-2.67 (-0.57%)

USD 122.24B
REGN Regeneron Pharmaceuticals Inc

+8.75 (+0.84%)

USD 115.08B
MRNA Moderna Inc

-1.00 (-0.74%)

USD 51.07B
BNTX BioNTech SE

-1.24 (-1.44%)

USD 24.18B
ARGX argenx NV ADR

+6.60 (+1.70%)

USD 23.44B
ALNY Alnylam Pharmaceuticals Inc

+8.30 (+5.27%)

USD 20.37B
GMAB Genmab AS

+0.15 (+0.58%)

USD 18.17B
BGNE BeiGene Ltd

+0.57 (+0.37%)

USD 17.50B
BMRN Biomarin Pharmaceutical Inc

-0.93 (-1.10%)

USD 15.98B
RPRX Royalty Pharma Plc

+0.28 (+1.05%)

USD 15.90B

ETFs Containing GERN

CNCR Loncar Cancer Immunothera.. 3.92 % 0.79 %

+0.15 (+0%)

USD 0.02B
WBIO:LSE WisdomTree BioRevolution .. 2.90 % 0.00 %

+23.10 (+0%)

USD 3.00M
WDNA:LSE WisdomTree BioRevolution .. 2.90 % 0.00 %

+0.20 (+0%)

USD 3.00M
WDNA 2.73 % 0.00 %

N/A

N/A
WRNA:XETRA WisdomTree BioRevolution .. 2.15 % 0.00 %

+0.25 (+0%)

USD 2.77M
BBC Virtus LifeSci Biotech Cl.. 1.84 % 0.79 %

+0.53 (+0%)

USD 0.01B
QQQS Invesco NASDAQ Future Gen.. 0.95 % 0.00 %

+0.25 (+0%)

USD 8.10M
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

+8.56 (+0%)

USD 1.01B
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

+0.65 (+0%)

USD 0.27B
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

+2.49 (+0%)

USD 7.07B
ISMD Inspire Small/Mid Cap Imp.. 0.00 % 0.62 %

-0.05 (0%)

USD 0.18B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 75.36% 88% B+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 75.36% 88% B+ 93% A
Trailing 12 Months  
Capital Gain 20.52% 75% C 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.52% 75% C 71% C-
Trailing 5 Years  
Capital Gain 143.42% 86% B+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 143.42% 85% B 86% B+
Average Annual (5 Year Horizon)  
Capital Gain 27.83% 79% B- 84% B
Dividend Return 27.83% 79% B- 84% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 55.54% 50% F 30% F
Risk Adjusted Return 50.11% 93% A 80% B-
Market Capitalization 0.34B 89% A- 81% B-

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 8.64 17% 13%
Price / Cash Flow Ratio -13.24 85% 85%
Price/Free Cash Flow Ratio -10.85 88% 85%
Management Effectiveness  
Return on Equity -60.04% 58% 28%
Return on Invested Capital -84.13% 35% 14%
Return on Assets -28.94% 53% 19%
Debt to Equity Ratio 14.14% 50% 66%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector